Entries by admin

4P-Pharma at BIO Europe Spring 2021

Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis. The Seal of Excellence is a high-quality label awarded by a panel […]

Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens […]

4P-Pharma at the Biotech Showcase 2021 online

Our chairwoman, Revital Rattenbach, will attend the Biotech Showcase, January 11th – 15th online. Contact us via the partnering platform or by e-mail to schedule a virtual meeting and discuss collaboration opportunities. For more information : https://informaconnect.com/biotech-showcase/

Happy New Year 2021 !

The entire 4P-Pharma team wishes you a happy 2021 ! May this new year be a source of achievement and joy for you and your loved ones Design by Valérie Baudry

4Moving Biotech au congrès de la SFR

Le Pr. Francis Berenbaum (chef du service de Rhumatologie de l’Hôpital Saint-Antoine et professeur de rhumatologie à Sorbonne Université, Paris) présentera nos résultats sur le projet 4P004 au 33ème congrès de la Société Française de Rhumatologie (SFR), du 13 au 16 décembre 2020, édition digitale. Sa présentation, intitulée « Le liraglutide comme traitement intra-articulaire potentiel […]

4P-Pharma will give a talk during the DDIP 2020

4P-Pharma’s CSO, Patrice Denèfle, will give a talk on 4P004 : « Accelerating therapeutic innovation for patient through drug repurposing : a use case in Osteoarthritis » at the Drug Discovery Innovation Programme (DDIP) virtual meeting organized by the World BI, on November, 17th 2020, 10:00 a.m CET. To learn more about 4P-Pharma, our pipeline […]